A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

Citations Over TimeTop 10% of 2012 papers

Related Papers

• → Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma(2021)11 cited
• → Selection of Patients with Hepatocellular Carcinoma for Sorafenib(2009)36 cited
• The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells.(2019)
• Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.(2014)
• → Μελέτη της επιδράσεως του αντιαγγειογενετικού παράγοντα sorafenib στην ηπατική αναγέννηση(2015)